Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This multicenter observational cohort study is based on a patient registry designed to systematically collect uniform real-world clinical data from elderly patients with Hodgkin lymphoma (HL) in China. The registry captures demographic characteristics, disease features, laboratory parameters, treatment patterns, and longitudinal survival outcomes to support predefined scientific objectives.
The primary analysis uses retrospectively collected registry data, with prospectively accrued data incorporated for external validation of a prognostic prediction model. This registry-based study aims to improve risk stratification and inform individualized clinical decision-making for elderly patients with HL in routine clinical practice.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Elderly patients with Hodgkin lymphoma | Observational Cohort |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival (OS) | Overall survival (OS) is defined as the time from diagnosis to death from any cause. | From date of diagnosis until death from any cause, assessed up to 60 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Progression-Free Survival (PFS) | Progression-free survival (PFS) is defined as the time from diagnosis to disease progression or death from any cause. | From date of diagnosis until the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 60 months. |
| Disease-Free Survival (DFS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study population consists of elderly patients aged 60 years or older with histologically confirmed Hodgkin lymphoma. Eligible patients include those diagnosed with classical Hodgkin lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma who were treatment-naïve at initial diagnosis.
All patients have complete clinical, pathological, and follow-up data available. Patients with other concurrent malignant tumors, severe hepatic or renal dysfunction, or missing more than 20% of required clinical data are excluded from the study.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tianjin Cancer Hospital | Tianjin | Tianjin Municipality | 300060 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006689 | Hodgkin Disease |
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Disease-free survival (DFS) is defined as the time from remission to disease relapse or death from any cause. |
| From date of first documented remission until disease relapse or death from any cause, whichever occurs first, assessed up to 60 months. |
| Event-Free Survival (EFS) | Event-free survival (EFS) is defined as the time from diagnosis to treatment failure, disease relapse, or death from any cause. | From date of diagnosis until treatment failure, disease relapse, or death from any cause, whichever occurs first, assessed up to 60 months. |
| Proportion of Participants With Disease Progression or Death Within 24 Months From Diagnosis (POD24) | Progression of disease within 24 months (POD24) is defined as the occurrence of documented disease progression or death from any cause within 24 months from the date of diagnosis. | From date of diagnosis to 24 months after diagnosis. |
| D008206 |
| Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |